Klotho Neuroscience, Inc., formerly ANEW Medical, Inc., is a specialty pharmaceutical company. The Company specializes in the development of diagnostics and novel disease-modifying therapies for neurological and age-related disorders. The Company focuses on central nervous systems (CNS) diseases utilizing cell and gene therapies to mitigate age-related pathologies such as Alzheimer's disease (AD), dementia symptoms and neuromuscular diseases. It has exclusive worldwide rights to develop and commercialize product platforms based on its proprietary isoform transcribed from the human Klotho gene referred to as secreted Klotho or s-KL. This s-KL protein or gene therapy has been recognized for its potential to mitigate age-related pathologies such as ALS, Alzheimer's and Parkinson's Disease. Its lead gene therapy product candidates are AMI-101 (AAV9-CMV-sKL) (Alzheimer's disease), and AMI-202 (AAVmyo-Des-sKL) gene therapy product for treatment and prevention of Lou Gehrig's disease.